Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.


Journal Article

BACKGROUND: The Dialysis Access Consortium (DAC) was developed to investigate interventions to improve hemodialysis vascular access outcomes. The autogenous arteriovenous fistula created by direct connection of native artery to vein is the recommended vascular access for hemodialysis. However, it fails frequently due to clotting after surgery. PURPOSE: The DAC Early AV Fistula Thrombosis Trial tests the hypothesis that clopidogrel can prevent early fistula failure and increase the number of fistulas that ultimately become usable for hemodialysis access. This is one of two initial and concurrent trials being performed by the DAC. The companion trial investigates pharmacologic approaches to prevent venous stenosis leading to AV graft failure. METHODS: This is a multicenter, randomized, double-blind, placebo-controlled trial that will enroll 1,284 patients over four years. Patients undergoing creation of a new native arteriovenous (AV) fistula are randomized to treatment with clopidogrel or placebo for six weeks following fistula creation surgery. The primary outcome is fistula patency at six weeks. The major secondary outcome is fistula suitability for dialysis. RESULTS: This paper examines key aspects of this study that have broad relevance to trial design including: 1) the selection of an intermediate event as the primary outcome, 2) timing of the intervention to balance efficacy and safety concerns, 3) ethical considerations arising from required modifications of concomitant drug therapy, and 4) choosing an efficacy or effectiveness evaluation of the intervention. CONCLUSIONS: This is the first, large, multicenter trial evaluating a pharmacologic approach to prevent early AV fistula failure and promote more usable fistulas for hemodialysis. The methodologic challenges identified and addressed during the development of this trial should help to inform the design of future vascular access trials, and are relevant to clinical trials addressing a wide range of questions.

Full Text

Duke Authors

Cited Authors

  • Dember, LM; Kaufman, JS; Beck, GJ; Dixon, BS; Gassman, JJ; Greene, T; Himmelfarb, J; Hunsicker, LG; Kusek, JW; Lawson, JH; Middleton, JP; Radeva, M; Schwab, SJ; Whiting, JF; Feldman, HI; DAC Study Group,

Published Date

  • 2005

Published In

Volume / Issue

  • 2 / 5

Start / End Page

  • 413 - 422

PubMed ID

  • 16317810

Pubmed Central ID

  • 16317810

International Standard Serial Number (ISSN)

  • 1740-7745

Digital Object Identifier (DOI)

  • 10.1191/1740774505cn118oa


  • eng

Conference Location

  • England